National

Ukraine, Russia both report new airstrikes

Jan 19, 2024

Moscow [Russia], January 19: Both Ukraine and Russia again reported numerous airstrikes on their territory during the night and in the early hours of Thursday morning.
The Ukrainian Air Force said the nation's air defence system shot down 22 of 33 drones during the night and that some drones had not reached their targets. Russia's attacks mainly focused on the eastern and southern regions of the country, including Kharkiv, the Ukrainian Air Force said.
Ukrainian authorities said that 11 houses and 134 apartments were damaged as a result of the nighttime attacks in the southern Ukrainian port city of Odessa. A rocket attack was also reported on the eastern Ukrainian region of Kharkiv - from the Russian Belgorod region.
The Russian authorities in turn said that Ukraine had carried out drone and missile attacks. The governor of Belgorod, Vyacheslav Gladkov, said on Thursday morning that Russian air defences shot down 10 Ukrainian missiles. One woman was injured in an attempted strike and the windows of one house were smashed, he said.
Russia began its full-invasion of Ukraine in February 2022. In its defence campaign, Ukraine has repeatedly shelled Russian territory - both in the border region and in the hinterland.
Source: Qatar Tribune

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025